Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1619 1627 1653
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18255575 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | Non-Final OA | AMGEN INC. |
| 18557775 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF XANTHINE OXIDASE INHIBITOR | Non-Final OA | LG CHEM, LTD. |
| 17920574 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17421671 | Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders | Final Rejection | Texas Tech University System |
| 18549546 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS IN THE TREATMENT OF HALLUCINATIONS AND DEMENTIA-RELATED PSYCHOSIS | Non-Final OA | Eli Lilly and Company |
| 18880882 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | Non-Final OA | SHANGHAI JIAO TONG UNIVERSITY |
| 18546116 | MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | Non-Final OA | BeyondSpring Pharmaceuticals, Inc. |
| 18407998 | USE OF SOBETIROME AND PRODRUGS AND DERIVATIVES THEREOF FOR TREATING PITT-HOPKINS SYNDROME | Non-Final OA | Oregon Health & Science University |
| 17616124 | Salt Forms of a Kinase Inhibitor | Non-Final OA | Exelixis, Inc. |
| 18256307 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES IN PATIENTS TAKING BRIVARACETAM | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18036730 | CRYSTAL FORM OF FREE BASE OF INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE AND PREPARATION METHOD AND APPLICATION OF CRYSTAL FORM | Final Rejection | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | Non-Final OA | Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center |
| 17410459 | METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS | Final Rejection | HUYABIO International, LLC |
| 18254573 | AMINOHETEROARYL KINASE INHIBITORS | Non-Final OA | ALLORION THERAPEUTICS INC |
| 18254261 | NOVEL PAR-2 INHIBITORS | Non-Final OA | DOMAIN THERAPEUTICS |
| 18037999 | COMPOUNDS, COMPOSITIONS, AND METHODS | Non-Final OA | Tenvie Therapeutics Inc |
| 18253481 | TREATMENT OF KRAS MUTANT CANCERS | Non-Final OA | MEI Pharma, Inc. |
| 17912749 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Final Rejection | COCRYSTAL PHARMA, INC. |
| 17758241 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | Non-Final OA | LEGOCHEM BIOSCIENCES, INC. |
| 17420007 | PYRROLOBENZODIAZEPINE DIMER COMPOUND WITH IMPROVED SAFETY AND USE THEREOF | Final Rejection | LEGOCHEM BIOSCIENCES, INC. |
| 17906288 | TREATMENT METHODS | Non-Final OA | Levon Michael KHACHIGIAN |
| 17769337 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | Non-Final OA | HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD. |
| 17622382 | Cannabinoid Conjugate Molecules | Non-Final OA | Diverse Biotech, Inc. |
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | Non-Final OA | Intercept Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy